Introduction

W
ith highly skilled staff, world-class technologies, reliable infrastructure and utilities, world-class regulatory policies, private sector innovation and government support, Singapore is one of most attractive locations in the Asia Pacific to invest in biotechnology.
International free trade has always been a top priority for the Singaporean government. This decade has seen the significant increase of investments in Singapore's biotechnology sector. If Singapore's biotechnology sector is to maintain its competitive advantage, it must have a strategy and undertake regular formal marketing audits and planning exercises.
A marketing audit is a systematic and objective scan of the internal and external environments affecting Singapore's biotechnology sector. Such an audit is a major precursor to the planning or strategy development in Singapore's biotechnology sector. It is important for this sort of exercise to be ongoing so that Singapore can anticipate and respond to the global changes in biotechnology.
As it supplies the information for making decisions, the marketing audit is, perhaps, the most important stage of the market planning and management of the Singapore biotechnology sector. It provides the intelligence from which corporate biotechnology strategies can be developed. The results of marketing auditing (usually summarized in a SWOT format) will indicate the general direction in which the Singapore biotechnology industry will grow towards. It will also highlight the product and market opportunities in biotechnology.
SWOT (Strengths, Weaknesses, Opportunities and Threats)
A central feature of strategic management is the ability to adapt optimally to a changing external environment. To do so, a sector must first have a good understanding of what is happening both within and outside of the industry.
The analysis of a sector's resources is often referred to as an analysis of strengths and weakness. The acronym SWOT describes the entire process whereby the strengths and weakness in the internal environment are analyzed in conjunction with the opportunities and threats arising from the external environment.
The strengths will increase the Singapore industry's capabilities and its likely success in the global market. The weaknesses will reveal the limitations of the capabilities of the Singapore biotechnology industry. Both the strengths and weakness will help in the microenvironmental analysis of the market auditing.
The opportunities will indicate how Singapore biotechnology can make inroads into the global biotechnology market. The threats will reveal which other nations may be a threat to the success of Singapore's biotechnology sector. Both the opportunities and threats will scan the changes or activities of the macroenvironment in the Singapore biotechnology sector.
The success of Singapore's biotechnology sector is dependent largely upon the effectiveness and efficiency of the interface between the external and internal environments.
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Analysis
A survey was sent to all biotechnology stakeholders in Singapore between 20 March and 10 April 2006. In the survey, participants were asked to comment on the strengths, weaknesses, opportunities and threats (SWOT analysis) of Singapore's biotechnology industry. It was stated in the survey that the information provided would be strictly confidential and no participant identities would be revealed with only the overall results published. This approach was meant to ensure that independent views were expressed in the survey truthfully. The survey participants were asked to rate (a rating of 1 being the lowest and 10 being the highest) on the overall strengths of Singapore biotechnology (Table 1) The following views were expressed in the Singapore Biotechnology Industry Survey.
Strengths
In general, most people highlighted Singapore's friendly environment, high standard of living, democratic society, liberal laws, efficient administration, safety, positive image and, the relatively low tax regime as important factors in attracting expatriates and young scientists to Singapore.
In addition, those surveyed commented on the considerable funds that the Singapore government had expended in creating new research institutes and small companies. These research institutes and companies had been important in creating new jobs and many opportunites for scientists and managers who wish to invest in biotechnology in Singapore. The Singapore government was considered to be actively promoting the biotechnology industry with favorable incentives for investors. Building the Biopolis was also a highlight in many of the survey participants' responses.
Many foreign biotechnology companies selected Singapore because of its excellent infrastructure. Academics working closely with A*STAR (Agency for Science, Technology and Research) institutes were able to exchange ideas and technological innovations easily.
Singapore's legal system which supports stem cell research, animal research and clinical trials; its strong base for research and development (R & D); robust IP systems; and good regulatory policies were key features of Singapore's biotechnology sector. Furthermore, Singapore's political stability; its ability to attract foreign talent; its significant relationship with multinational companies (MNC); its access to Asia Pacific disease populations; its global talent pools; and its established education infrastructure were also identified as the main attractions of Singapore's biotechnology sector.
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Weaknesses
Many participants in the survey commented that private venture capitalists do not capitalize enough in Singapore's biotechnology industry. However, the Singapore government funding is very excessive. This results in the lack of competition among private venture capitalists. Furthermore, the Singapore government funding is not equally available to the private sector for local Singaporean companies. Perhaps, in future, more venture capitalists will invest in Singapore biotechnology.
The survey also identified the fact that the Singapore biotechnology workforce has very few translational scientists and clinical scientists with extensive experience and track records. This creates a serious bottleneck.
Also, another problem was that the basic science sector and the clinical trials are almost not universally linked. This results in an extremely weak clinical trials sector with a few clinicians who are able to conceptualize trials and put up trial protocols. On top of this, very few patients participate in clinical trial protocols. There was also insufficient resources allocated to animal facilities, despite the conducive legislation.
Another weakness emanates primarily from the lack of funding for follow on development and an inability to tap into the local venture capital market for fund raising. In addition, research directions are too centralized and overly cautious. This conservative culture results in an aversion to risks and failures.
Some of those surveyed expressed the view that the low quality of consultancy and construction services (biotechnology and life science facility planning and construction) were pitfalls. Other critical factors identified included a lack of local scientists (as a result the education system); a poor track record in research and patents; higher R & D operating costs; and weak university and industry collaborations. Excessive Singapore government and BioSingapore intervention, government control and red tape were also mentioned as significant barriers. Historically, there was an absence of a R & D culture, thus resulting in a lack of qualified trained personnel. A high dependency on foreign skilled workers and a young scientists cluster were also mentioned in the survey responses.
Opportunities
Many of those surveyed felt that the Singapore's biotechnology sector should be poised to take advantage of a new and rapidly growing sector with no established competitors in the Asia Pacific at present. The survey identified opportunities existing in public funding and regulatory support for biomedical research in the areas of stem cells, vaccine production, pharmaceuticals, cardiac development, nanotechnology, alternative energies and water.
To maintain the growth of Singapore biotechnology, Singapore must have a competitive edge over other ASEAN countries in terms of the human capital and governmental incentives. This is an area that the Singapore is currently building upon.
Being geographically central and having ethical/cultural access to the other countries in the Asia Pacific are seen as positive contributions towards the growth of Singapore's biotechnology industry. In addition, collaborative projects between multinationals are most welcomed in the Singapore biotechnology sector.
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Recently, Singapore announced the Science and Technology Plan 2010. Under this plan, approximately S$7.5 billion (US$4.8 billion) will be committed to fund public and private R& D over the next five years. This was regarded as a huge step forward in facilitating Singapore to become the top five global biotechnology hub.
The biomedical sector was identified as a key strategic sector that attracts current funding with the five key areas being drug discovery, bioimaging, stem cells, cohort studies and biomarkers research.
Other ASEAN countries in the region have relatively weak IP enforcement. Some participants of the survery stated that Singapore was a popular choice for western multinationals as a gateway to the Asia Pacific market. In addition, they mentioned that Singapore is a good place to explore new avenues of growth, such as the commercialization of China's Traditional Chinese Medicine (TCM).
Threats
Singapore is relatively new to biotechnology investment and it may take several years before it enjoys the fruits of its investment. Industry players in the Singapore biotech sector are hoping that this enthusiasm and new investment will continue until that day eventuates.
Many of the participants of the survey noted that other Asian countries, such as the India, South Korea, Malaysia, Thailand and China, with their lower costs and economies of scale, could effectively undercut biotech endeavours in Singapore before the industry becomes sufficiently established.
Thus, Singapore must move much faster (than its present pace) to take advantage of the current window of opportunity. The global race for ground breaking patents; global competition for knowledgeable workers; the lack of entrepreneurial spirit; and the lack of private/personal funds for startup companies are the major threats to Singapore's biotechnology sector.
Conclusion
In general, a SWOT analysis forms the basis of most strategic plans. The strategic analysis of an industry requires a thorough and objective analysis of what an industry is currently doing, what it is capable of doing and what it should be doing.
Whilst it is relatively simple to identify what an industry is currently doing, it is often extremely difficult to agree on what it should be doing. Understanding the strengths and weakness of an industry (in a strategic sense) requires information not only about the skill bank of the industry, it also requires information about the competitive advantage and resources of its competitors. As a result, there is good reason to believe that, more and more, successful industries are informationorientated ones.
The information presented in this article is based upon the Singapore Biotechnology Survey. This survey involves various stakeholders in Singapore's biotechnology sector. It is meant to provide a useful insight into the future strategic planning required to animate Singapore's biotechnology sector.
